Physician

Christopher B George, M. D.

According to 2025 Medicare claims, Christopher George, M. D. (NPI: 1881646156) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33607-6214.

George's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 653 traditional Medicare patients, billed 152,805 HCPCS/CPT codes, and received $2,045,977 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 714 prescription claims across 163 beneficiaries totaling $2,336,368 in drug costs, led by Ibrance (Palbociclib). 2022 DME data shows 15 claims. Open Payments data shows 7 records totaling $164. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $987,333 to $2,336,368. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	991	176,680	$2,888,558
2016	1,028	166,747	$2,440,383
2017	1,071	199,922	$2,653,412
2018	1,139	183,547	$2,813,362
2019	1,369	175,210	$3,045,402
2020	1,232	154,047	$2,713,082
2021	1,193	151,684	$2,858,717
2022	975	181,888	$2,861,321
2023	766	131,235	$2,417,565
2024	653	152,805	$2,045,977

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,258	$987,333
2016	218	1,203	$1,043,298
2017	232	1,217	$1,173,560
2018	215	1,015	$1,287,252
2019	198	912	$1,515,898
2020	185	781	$1,506,132
2021	165	781	$1,765,947
2022	177	783	$1,880,410
2023	148	669	$2,402,286
2024	163	714	$2,336,368

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	61	$3,885
2016	N/R	N/R	N/R
2017	14	55	$11,491
2018	16	29	$5,239
2019	N/R	11	$2,144
2020	N/R	33	$2,322
2021	13	16	$2,050
2022	N/R	15	$2,112
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	387	1,170	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	187	218	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	315	605	$13
36415	Insertion of needle into vein for collection of blood sample	486	1,380	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	490	1,488	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	44	1,232	$710,529
Revlimid	Lenalidomide	35	924	$586,733
Xtandi	Enzalutamide	14	420	$194,740
Exemestane	Exemestane	20	780	$3,884
Anastrozole	Anastrozole	127	9,767	$1,567

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$164	Mirati Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher B. George, M. D.?

Tedicare shows public-source Medicare data for Christopher B. George, M. D. (NPI 1881646156), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher B. George, M. D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher B. George, M. D.?

Christopher B. George, M. D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Christopher B. George, M. D. have Open Payments data?

Christopher B. George, M. D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.